Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor

Akira Sawaki, Kazuhiko Ohashi, Kenji Yamao, Ken Ichi Inada, Yasuhiro Shimizu, Akira Matsuura, Tuneya Nakamura, Takashi Suzuki, Kazuo Hara, Kenji Okubo, Ryuzo Ohno

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors. The molecular etiology is the result of mutations in the c-Kit gene. The mutant c-Kit proteins, which are activated without a stem cell factor, contribute to the tumor development. STI571 selectively inhibits c-Kit, BCR-ABL, and PDGFR tyrosine kinases. Based on this potential to inhibit critical c-Kit function in GISTs, case studies have reported effective outcomes following treatment with STI571. This case report describes a highly effective use of STI571 in a 54-year-old woman with multiple liver metastases from a GIST originating in the duodenum.

Original languageEnglish
Pages (from-to)690-694
Number of pages5
JournalJournal of Gastroenterology
Volume38
Issue number7
DOIs
Publication statusPublished - 01-07-2003
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Fingerprint Dive into the research topics of 'Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor'. Together they form a unique fingerprint.

  • Cite this

    Sawaki, A., Ohashi, K., Yamao, K., Inada, K. I., Shimizu, Y., Matsuura, A., Nakamura, T., Suzuki, T., Hara, K., Okubo, K., & Ohno, R. (2003). Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor. Journal of Gastroenterology, 38(7), 690-694. https://doi.org/10.1007/s00535-002-1124-1